RecruitingNot Applicable

Unequal Placental Sharing in Monochorionic Diamniotic Twins: an Observational Study

Belgium393 participantsStarted 2016-04

Plain-language summary

This is an observational study in 3 cohorts of monochorionic diamniotic (MCDA) twins. The aim of the study is to assess whether unequal placental sharing can be predicted in pregnancy and whether it is predictive of pregnancy outcome.

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * MCDA cohort * Ongoing monochorionic diamniotic twin pregnancy between 11 and 14 weeks, as determined by the crown rump length of the larger twin in spontaneous conceptions and by the date of insemination or embryonic age at replacement in pregnancies resulting from subfertility treatment * Women aged 18 years or more, who are able to consent * Written informed consent to participate in this study, forms being approved by the Ethical Committees * TTTS cohort * Monochorionic diamniotic twin pregnancy, with gestational age defined in the first trimester as mentioned above * Complicated by TTTS according to the definition used in the Quintero staging of TTTS (DVP of donor \< 2 cm and DVP of receptor \> 8 cm before 20 weeks or \> 10 cm after 20 weeks * Undergoing laser surgery for TTTS * Women aged 18 years or more, who are able to consent * Written informed consent to participate in this study, forms being approved by the Ethical Committees * sIUGR cohort * Monochorionic diamniotic twin pregnancy, with gestational age defined in the first trimester as mentioned above * Complicated by sIUGR defined as a discordance in EFW of ≥ 20%, with the percentage of discordance being calculated as (EFW larger twin - EFW smaller twin)/EFW larger twin x 100. * Women aged 18 years or more, who are able to consent * Written informed consent to participate in this study, forms being approved by the Ethical Committees Exclusion Criteria: * Age \< …

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

MCDA cohort: the association between unequal sharing and risk of fetal or neonatal loss (assessed by review of obstetric and pediatric records)

Timeframe: 2 weeks after expected date of birth

TTTS cohort: the association between unequal sharing and intrauterine fetal death (assessed by review of obstetric records)

Timeframe: 2 weeks after expected date of birth

sIUGR cohort: the association between unequal sharing and risk of fetal or neonatal loss and birth prior to 34 weeks (assessed by review of obstetric and pediatric records)

Timeframe: 2 weeks after expected date of birth

Trial details

NCT IDNCT03024918

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06

Contact for this trial

Isabel Couck

+32 16 34 22 94 isabel.couck@uzleuven.be

View on ClinicalTrials.gov More Monochorionic Twins trials

Who can participate

Age range

18 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

MCDA cohort: the association between unequal sharing and risk of fetal or neonatal loss (assessed by review of obstetric and pediatric records)

Timeframe: 2 weeks after expected date of birth

TTTS cohort: the association between unequal sharing and intrauterine fetal death (assessed by review of obstetric records)

Timeframe: 2 weeks after expected date of birth

sIUGR cohort: the association between unequal sharing and risk of fetal or neonatal loss and birth prior to 34 weeks (assessed by review of obstetric and pediatric records)

Timeframe: 2 weeks after expected date of birth